In addition, there is accumulating scientific interest in the potential role of some glucose-lowering agents (such as pioglitazone, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors) in patients with NAFLD/MAFLD, as they exert benefits on hepatic fat content and steatohepatitis, as well as benefits on cardiorenal outcomes independent of the presence of T2DM [21,23,54,55]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.